{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:42:21Z","timestamp":1791052941799,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Essential thrombocythemia (ET) may occur in women of childbearing age. To investigate the risk of pregnancy complications, we studied 103 pregnancies that occurred in 62 women with ET. The 2-tailed Fisher exact test showed that pregnancy outcome was independent from that of a previous pregnancy. The rate of live birth was 64%, and 51% of pregnancies were uneventful. Maternal complications occurred in 9%, while fetal complications occurred in 40% of pregnancies. The Mantel-Haenszel method showed that fetal loss in women with ET was 3.4-fold higher (95% confidence interval [CI]: 3-3.9; P &lt; .001) than in the general population. Half of the women studied carried the JAK2 (617V&gt;F) mutation, and a multivariate logistic regression model identified this mutation as an independent predictor of pregnancy complications (P = .01). Neither the platelet count nor the leukocyte count was a risk factor. JAK2 (617V&gt;F)\u2013positive patients had an odds ratio of 2.02 (95% CI: 1.1 - 3.8) of developing complications in comparison with JAK2 (617V&gt;F)\u2013negative patients. Aspirin did not prevent complication in JAK2 (617V&gt;F)\u2013positive patients and appeared to worsen outcome in JAK2 (617V&gt;F)\u2013negative patients. A relationship was found between JAK2 (617V&gt;F) and fetal loss (P = .05). This study indicates that patients carrying the JAK2 (617V&gt;F) mutation have higher risk of developing pregnancy complications.<\/jats:p>","DOI":"10.1182\/blood-2007-01-071068","type":"journal-article","created":{"date-parts":[[2007,4,11]],"date-time":"2007-04-11T03:04:33Z","timestamp":1176260673000},"page":"485-489","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":145,"title":["Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V&gt;F) mutation"],"prefix":"10.1182","volume":"110","author":[{"given":"Francesco","family":"Passamonti","sequence":"first","affiliation":[{"name":"Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luigia","family":"Randi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences\u2014Chirurgiche, Sezione Medicina Interna (CLOPD), University of Padova Medical School, Padova;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Pungolino","sequence":"additional","affiliation":[{"name":"Division of Hematology, Ospedale Niguarda Ca' Granda, Milan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Elena","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pietra","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Scapin","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences\u2014Chirurgiche, Sezione Medicina Interna (CLOPD), University of Padova Medical School, Padova;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Tezza","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences\u2014Chirurgiche, Sezione Medicina Interna (CLOPD), University of Padova Medical School, Padova;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remigio","family":"Moratti","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Pascutto","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Fabris","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences\u2014Chirurgiche, Sezione Medicina Interna (CLOPD), University of Padova Medical School, Padova;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Morra","sequence":"additional","affiliation":[{"name":"Division of Hematology, Ospedale Niguarda Ca' Granda, Milan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Lazzarino","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111714223918900_B1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"2019111714223918900_B2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia.","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"key":"2019111714223918900_B3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2141.2005.05400.x","article-title":"Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.","volume":"129","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111714223918900_B4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-2006-942763","article-title":"Essential thrombocythemia\/polycythemia vera and pregnancy: the need for an observational study in Europe.","volume":"32","author":"Griesshammer","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2019111714223918900_B5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1521-6926(03)00019-7","article-title":"Thrombocythaemia and pregnancy.","volume":"16","author":"Elliott","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111714223918900_B6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1034\/j.1600-0609.2001.00367.x","article-title":"A single institutional experience with 43 pregnancies in essential thrombocythemia.","volume":"66","author":"Wright","year":"2001","journal-title":"Eur J Haematol"},{"key":"2019111714223918900_B7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111714223918900_B8","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"2019111714223918900_B9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"2019111714223918900_B10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111714223918900_B11","first-page":"177","article-title":"Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.","volume":"23","author":"Murphy","year":"1986","journal-title":"Semin Hematol"},{"key":"2019111714223918900_B12","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"2019111714223918900_B13","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms.","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2019111714223918900_B14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"2019111714223918900_B15","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood-2006-04-014746","article-title":"Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative.","volume":"108","author":"Randi","year":"2006","journal-title":"Blood"},{"key":"2019111714223918900_B16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/369064a0","article-title":"Mutation in blood coagulation factor V associated with resistance to activated protein C.","volume":"369","author":"Bertina","year":"1994","journal-title":"Nature"},{"key":"2019111714223918900_B17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","article-title":"A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.","volume":"10","author":"Frosst","year":"1995","journal-title":"Nat Genet"},{"key":"2019111714223918900_B18","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","article-title":"A common genetic variation in the 3\u2032-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.","volume":"88","author":"Poort","year":"1996","journal-title":"Blood"},{"key":"2019111714223918900_B19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0609.2004.00324.x","article-title":"Pregnancy in essential thrombocythaemia: experience with 40 pregnancies.","volume":"73","author":"Niittyvuopio","year":"2004","journal-title":"Eur J Haematol"},{"key":"2019111714223918900_B20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0609.2000.90214.x","article-title":"Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies.","volume":"65","author":"Bangerter","year":"2000","journal-title":"Eur J Haematol"},{"key":"2019111714223918900_B21","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archinte.1995.00430110137015","article-title":"Outcome analysis of 34 pregnancies in women with essential thrombocythemia.","volume":"155","author":"Beressi","year":"1995","journal-title":"Arch Intern Med"},{"key":"2019111714223918900_B22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM199901073400102","article-title":"Increased frequency of genetic thrombophilia in women with complications of pregnancy.","volume":"340","author":"Kupferminc","year":"1999","journal-title":"N Engl J Med"},{"key":"2019111714223918900_B23","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJM200104193441607","article-title":"Genetic susceptibility to venous thrombosis.","volume":"344","author":"Seligsohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2019111714223918900_B24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/asheducation-2006.1.444","article-title":"Management of hereditary hypercoagulable disorders.","author":"Bockenstedt","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111714223918900_B25","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders.","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111714223918900_B26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbmt.2006.11.003","article-title":"Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.","volume":"13","author":"Hoffman","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111714223918900_B27","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.leu.2404209","article-title":"A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.","volume":"20","author":"Vannucchi","year":"2006","journal-title":"Leukemia"},{"key":"2019111714223918900_B28","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"2019111714223918900_B29","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","article-title":"Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.","volume":"108","author":"Moliterno","year":"2006","journal-title":"Blood"},{"key":"2019111714223918900_B30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000057634","article-title":"Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no. A comparative analysis of the literature.","volume":"107","author":"Vantroyen","year":"2002","journal-title":"Acta Haematol"},{"key":"2019111714223918900_B31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(94)92633-6","article-title":"CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women: CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"2019111714223918900_B32","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood-2005-08-3526","article-title":"Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia.","volume":"107","author":"Schafer","year":"2006","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/2\/485\/1291968\/zh801407000485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/2\/485\/1291968\/zh801407000485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T19:22:52Z","timestamp":1574018572000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/2\/485\/22882\/Increased-risk-of-pregnancy-complications-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,15]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,7,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-01-071068","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,15]]}}}